|
|
|
| Statins, diabetes, obesity, nonalcoholic fatty liver disease, and hepatocellular carcinoma |
| Jun Han a , Wen-Tao Yan a , b , Bing Quan a , b , Ming-Da Wang a , Tian Yang a , ∗ |
a Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, (No. 225) Changhai Road, Shanghai 200438, China
b Department of Clinical Medicine, the Second Military Medical University, No.800 Xiangyin Road, Shanghai 200433, China
∗ Corresponding author.
E-mail address: yangtianehbh@smmu.edu.cn (T. Yang). |
|
|
|
|
Abstract We read with great interest the recent article by Chang et al. [1] . By analyzing the data of 1350 cirrhotic patients, the authors concluded that statin significantly decreases the risk of decompensation of cirrhosis, mortality and hepatocellular carcinoma (HCC) incidence, and these effects are dose dependent. Herein, we would like to comment as followings:
|
|
|
|
|
|
|
|
|
2019, Vol. 18 
